Fig. 4

Disease characteristics and initial pharmacological treatment algorithm. ^aConsider if highly symptomatic (e.g. CAT > 20). ^bConsider if EOS ≥0.3 × 10⁹ cells/L (≥300 cells/mm³). Reproduced with permission from: Global Initiative for Chronic Obstructive Lung Disease 2021 Report; Figure 4.2. Available from https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf, accessed 18 November 2020. CAT COPD assessment test, COPD chronic obstructive pulmonary disease, EOS eosinophil count, ICS inhaled corticosteroids, LABA long-acting β₂-agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council dyspnoea scale